Logo image of INCY

INCYTE CORP (INCY) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INCY - US45337C1027 - Common Stock

95.58 USD
+0.42 (+0.44%)
Last: 12/10/2025, 1:11:58 PM
Fundamental Rating

6

Taking everything into account, INCY scores 6 out of 10 in our fundamental rating. INCY was compared to 531 industry peers in the Biotechnology industry. INCY gets an excellent profitability rating and is at the same time showing great financial health properties. INCY is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, INCY could be worth investigating further for value and quality investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year INCY was profitable.
INCY had a positive operating cash flow in the past year.
INCY had positive earnings in 4 of the past 5 years.
Of the past 5 years INCY 4 years had a positive operating cash flow.
INCY Yearly Net Income VS EBIT VS OCF VS FCFINCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

With an excellent Return On Assets value of 18.78%, INCY belongs to the best of the industry, outperforming 96.61% of the companies in the same industry.
INCY has a Return On Equity of 25.55%. This is amongst the best in the industry. INCY outperforms 96.99% of its industry peers.
The Return On Invested Capital of INCY (19.88%) is better than 97.74% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INCY is significantly below the industry average of 18.22%.
The 3 year average ROIC (7.24%) for INCY is below the current ROIC(19.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 18.78%
ROE 25.55%
ROIC 19.88%
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
INCY Yearly ROA, ROE, ROICINCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

With an excellent Profit Margin value of 24.69%, INCY belongs to the best of the industry, outperforming 94.73% of the companies in the same industry.
INCY's Profit Margin has declined in the last couple of years.
INCY's Operating Margin of 26.10% is amongst the best of the industry. INCY outperforms 95.86% of its industry peers.
In the last couple of years the Operating Margin of INCY has declined.
Looking at the Gross Margin, with a value of 93.47%, INCY belongs to the top of the industry, outperforming 94.35% of the companies in the same industry.
INCY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 26.1%
PM (TTM) 24.69%
GM 93.47%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
INCY Yearly Profit, Operating, Gross MarginsINCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

7

2. Health

2.1 Basic Checks

INCY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for INCY has been reduced compared to 1 year ago.
Compared to 5 years ago, INCY has less shares outstanding
INCY has a worse debt/assets ratio than last year.
INCY Yearly Shares OutstandingINCY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
INCY Yearly Total Debt VS Total AssetsINCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

INCY has an Altman-Z score of 8.63. This indicates that INCY is financially healthy and has little risk of bankruptcy at the moment.
INCY's Altman-Z score of 8.63 is fine compared to the rest of the industry. INCY outperforms 79.47% of its industry peers.
INCY has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
The Debt to FCF ratio of INCY (0.03) is better than 96.23% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
INCY has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: INCY outperforms 44.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 8.63
ROIC/WACC2.26
WACC8.8%
INCY Yearly LT Debt VS Equity VS FCFINCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

A Current Ratio of 3.20 indicates that INCY has no problem at all paying its short term obligations.
The Current ratio of INCY (3.20) is worse than 62.90% of its industry peers.
A Quick Ratio of 3.13 indicates that INCY has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.13, INCY is doing worse than 61.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 3.13
INCY Yearly Current Assets VS Current LiabilitesINCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

6

3. Growth

3.1 Past

INCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 575.79%, which is quite impressive.
INCY shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.21% yearly.
Looking at the last year, INCY shows a quite strong growth in Revenue. The Revenue has grown by 18.09% in the last year.
The Revenue has been growing by 14.46% on average over the past years. This is quite good.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%

3.2 Future

Based on estimates for the next years, INCY will show a very strong growth in Earnings Per Share. The EPS will grow by 28.45% on average per year.
INCY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.17% yearly.
EPS Next Y428.71%
EPS Next 2Y147.09%
EPS Next 3Y90.86%
EPS Next 5Y28.45%
Revenue Next Year18.26%
Revenue Next 2Y14.51%
Revenue Next 3Y12.86%
Revenue Next 5Y1.17%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INCY Yearly Revenue VS EstimatesINCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
INCY Yearly EPS VS EstimatesINCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.89, which indicates a correct valuation of INCY.
Based on the Price/Earnings ratio, INCY is valued cheaper than 95.48% of the companies in the same industry.
INCY's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.29.
Based on the Price/Forward Earnings ratio of 11.86, the valuation of INCY can be described as reasonable.
Based on the Price/Forward Earnings ratio, INCY is valued cheaper than 97.55% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of INCY to the average of the S&P500 Index (23.51), we can say INCY is valued slightly cheaper.
Industry RankSector Rank
PE 14.89
Fwd PE 11.86
INCY Price Earnings VS Forward Price EarningsINCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaper than 95.86% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, INCY is valued cheaply inside the industry as 96.05% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 15.68
EV/EBITDA 11.36
INCY Per share dataINCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INCY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as INCY's earnings are expected to grow with 90.86% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y147.09%
EPS Next 3Y90.86%

0

5. Dividend

5.1 Amount

No dividends for INCY!.
Industry RankSector Rank
Dividend Yield N/A

INCYTE CORP

NASDAQ:INCY (12/10/2025, 1:11:58 PM)

95.58

+0.42 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners105.03%
Inst Owner Change1.22%
Ins Owners1.74%
Ins Owner Change-6.67%
Market Cap18.76B
Revenue(TTM)4.81B
Net Income(TTM)1.19B
Analysts75
Price Target96.26 (0.71%)
Short Float %4.94%
Short Ratio4.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)9.9%
PT rev (3m)14.6%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)6.19%
EPS NY rev (1m)0.19%
EPS NY rev (3m)10.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.68%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)2.86%
Valuation
Industry RankSector Rank
PE 14.89
Fwd PE 11.86
P/S 3.9
P/FCF 15.68
P/OCF 14.99
P/B 4.03
P/tB 4.29
EV/EBITDA 11.36
EPS(TTM)6.42
EY6.72%
EPS(NY)8.06
Fwd EY8.43%
FCF(TTM)6.1
FCFY6.38%
OCF(TTM)6.37
OCFY6.67%
SpS24.52
BVpS23.69
TBVpS22.29
PEG (NY)0.03
PEG (5Y)N/A
Graham Number58.5
Profitability
Industry RankSector Rank
ROA 18.78%
ROE 25.55%
ROCE 25.17%
ROIC 19.88%
ROICexc 48.14%
ROICexgc 55.55%
OM 26.1%
PM (TTM) 24.69%
GM 93.47%
FCFM 24.87%
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 59.08%
Cap/Sales 1.13%
Interest Coverage 250
Cash Conversion 92.81%
Profit Quality 100.71%
Current Ratio 3.2
Quick Ratio 3.13
Altman-Z 8.63
F-Score7
WACC8.8%
ROIC/WACC2.26
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y428.71%
EPS Next 2Y147.09%
EPS Next 3Y90.86%
EPS Next 5Y28.45%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year18.26%
Revenue Next 2Y14.51%
Revenue Next 3Y12.86%
Revenue Next 5Y1.17%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year366.76%
EBIT Next 3Y85.61%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%

INCYTE CORP / INCY FAQ

What is the fundamental rating for INCY stock?

ChartMill assigns a fundamental rating of 6 / 10 to INCY.


What is the valuation status for INCY stock?

ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.


How profitable is INCYTE CORP (INCY) stock?

INCYTE CORP (INCY) has a profitability rating of 7 / 10.


What is the valuation of INCYTE CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for INCYTE CORP (INCY) is 14.89 and the Price/Book (PB) ratio is 4.03.


What is the earnings growth outlook for INCYTE CORP?

The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 428.71% in the next year.